TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04257331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stars and Rain Education Institute for Autism (SREIA) Parent Training Programme
Description: The SREIA program is grounded in applied behavior analysis and developmental theories. It aims to reduce child behavioral problems and promote child development by improving parental attitudes and parenting styles. The program targets parent-child dyads from families of children with ASD aged between three and six years. It is delivered five days a week for 11 weeks. Fourteen two-hour lectures on weekly themes (such as knowledge of ASD, parent-child interaction, and behavior management techniques) are offered throughout the 11 weeks and attended by all participating parents. For the remaining time, additional training in ABA principles and practice are tailored for the different functioning groups. The program offers a combination of individual counselling and group sessions, as well as a mixture of didactic and interactive delivery modes. All sessions are delivered in person. Some sessions are only for parents and others are participated in by both parent and child.
Study: NCT05668247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FOOT BATH
Description: In general, foot bath is a type of relaxation and care performed by putting feet in water. Feet, as the organs carrying the whole body weight are the body parts where fatigue is felt most. In this study, a specially designed foot bath bucket was used in order to apply foot bath for the patients in the experimental group.
Study: NCT00829153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U Clip
Description: Interuppted nitional clips
Study: NCT03793439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial
Description: Tofacitinib 5mg oral table twice daily for 16 weeks

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: Spirometry testing at baseline, week 4, week 8, week 12, and week 16

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA Sequencing
Description: RNA sequencing test at baseline and week 16

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laboratory testing
Description: Laboratory testing at baseline and weeks 2, 4, 8, 12 and 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Taper corticosteroids starting at week 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5mg [Xeljanz] 1 year open-label extension
Description: After 16 weeks, subjects who meet the primary end-point will be permitted an optional one year open-label extension.
Study: NCT01781949

Intervention type: OTHER
Group type: OTHER
Intervention: A: Nontargeted rapid HIV screening
Description: Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.

Intervention type: OTHER
Group type: OTHER
Intervention: B: Enhanced targeted rapid HIV screening
Description: Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS \<30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.

Intervention type: OTHER
Group type: OTHER
Intervention: C: Traditional targeted rapid HIV screening
Description: Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
Study: NCT04217395

Intervention type: BEHAVIORAL
Intervention: Obese or overweight health subjects involved in the X-Ailes program (at least one contact with the health system navigator)
Description: The X-Ailes program is a face-to-face or telephone-based support program by health-system navigators and developed by a patients and public association to support overweight or obese care users.~The main objective of the study is to evaluate the efficacy of the X-ailes program on quality of life of overweight and obese people involved in the program.~Secondary objectives are to assess their overall health status, their health literacy level and their empowerment. The implementation study is guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance; Glasgow, Vogt, \& Boles, 1999) theoretical framework to determine whether the intervention objectives are being met and to understand the mechanisms of action of the device.
Study: NCT03347149

Intervention type: DEVICE
Intervention: Alarm Advisor Software
Description: Providing advice on alarm limits as part of routine medical care
Study: NCT01276821

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Epinephrine and Normal Saline (0.9%)
Description: 1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Epinephrine and Hypertonic Saline (3%)
Description: 1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
Study: NCT04022486

Intervention type: OTHER
Intervention: Incidence, management and risk factors of seizure
Description: Incidence of seizure, management (treatment, paraclinical examinations) and risk factors of seizure in children admitted for severe bronchiolitis
Study: NCT03576144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1265162
Description: Multiple rising inhaled doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple rising inhaled doses
Study: NCT05090956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mri
Study: NCT04250584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iSlpr™
Description: mandibular advancement device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SomnoDent® Classic
Description: mandibular advancement device
Study: NCT01716819

Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: dosages on one spot and 24h collection

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: dosages

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of sleep apnea syndrome

Intervention type: OTHER
Group type: OTHER
Intervention: Electrocardiogram

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose tolerance test

Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiography

Intervention type: OTHER
Group type: OTHER
Intervention: cardiac and abdominal magnetic resonance imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Ambulatory blood pressure monitoring

Intervention type: OTHER
Group type: OTHER
Intervention: Echotracking

Intervention type: OTHER
Group type: OTHER
Intervention: Pulse wave velocity

Intervention type: OTHER
Group type: OTHER
Intervention: Composition of body mass by Dual x-ray absorptiometry
Study: NCT00450580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosamprenavir/ritonavir
Description: Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fosamprenavir/ritonavir
Description: Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
Study: NCT00829153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional prolene anastomosis
Description: Continuous prolene anastomosis
Study: NCT02749734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subretinal transplantation
Description: Transplant hESC-RPE into subretinal space of patients with macular degeneration
Study: NCT02162862

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Counseling

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Counseling

Intervention type: DRUG
Group type: OTHER
Intervention: bupropion-SR
Study: NCT01499173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stroke Preparedness Intervention
Description: A faith-based, scientific theory-driven, peer-led behavioral intervention performed in a group setting in African American churches.
Study: NCT04055805

Intervention type: BEHAVIORAL
Intervention: Observational Analysis
Description: Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy

Intervention type: BEHAVIORAL
Intervention: Observational Analysis
Description: Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy

Intervention type: BEHAVIORAL
Intervention: Observational Analysis
Description: Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy

Intervention type: BEHAVIORAL
Intervention: Observational Analysis
Description: Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy

Intervention type: BEHAVIORAL
Intervention: Observational Analysis
Description: Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy

Intervention type: BEHAVIORAL
Intervention: Observational Analysis
Description: Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy

Intervention type: BEHAVIORAL
Intervention: Observational Analysis
Description: Studying the current state of the clinical approaches to bone diseases in breast cancer patients treated with adjuvant and/or hormone therapy
Study: NCT03408691

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fresh fermented dairy drink containing probiotic strain
Description: Fresh fermented dairy drink containing probiotic strain consumed as follows: one bottle (100g) BID for 6 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acidified dairy drink without ferment
Description: Acidified dairy drink without ferment consumed as follows: one bottle (100g) BID for 6 weeks.
Study: NCT01613040

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose on Day 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Multiple daily low doses of RO4917838 for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: Multiple daily oral high doses of RO4917838 for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RO4917838 placebo
Description: Oral daily doses of placebo to RO4917838 for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RO4917838 placebo
Description: Oral daily doses of placebo to RO4917838 for 10 days
Study: NCT00930202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conivaptan (Vaprisol)
Description: Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
Study: NCT03197207

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dragon and Tiger warring in lifting and thrusting
Description: Tight press slow insert in each acupoint through the superficial,intermediate, deep layer, then tight lifting slow withdraw needle through the deep, intermediate, superficial layer . Two acupoints (GB34, GB39) are manipulation in the process three times each during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dragon and Tiger warring in twisting-rotating
Description: When needle insert in each acupoint through the superficial,intermediate, deep layer, within each layer twisting thumb forward nine times, then twisting backward six times. Two acupoints (GB34, GB39) are manipulation in the process during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later.
Study: NCT02416726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nextseq500 sequencer
Description: The sequencer will be used to detect the gene mutations of the primary tumor, metastatic LN and peripheral blood samples obtained from patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nextseq500 sequencer
Description: The sequencer will be used to detect the gene mutations of the primary tumor, metastatic LN and peripheral blood samples obtained from patients.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nextseq500 sequencer
Description: The sequencer will be used to detect the gene mutations of the primary tumor, metastatic LN and peripheral blood samples obtained from patients.
Study: NCT01916408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wobenzym plus
Description: 3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PL 1
Description: 3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
Study: NCT00878124

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 co treatment
Description: CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Caps
Description: 3 caps twice a day continuously until pregnant or at the end of the study.
Study: NCT00722293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib (GW786034)
Description: Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated
Study: NCT01465581

Intervention type: PROCEDURE
Intervention: Division of the filum terminal
Description: Division of the filum is performed through a 6cm incision over the lumbosacral junction that can be oriented either longitudinally or transversely - to be hidden beneath underclothes or swim wear. A single level laminectomy provides sufficient exposure. The dural opening can be as short as 1cm. Under the microscope the filum is identified visually and separated from lower sacral rootlets with the aid of microelectrode stimulation. When a segment of the filum has been excised and sent for laboratory examination, the dura is closed and reinforced with fibrin glue. The wound is closed in layers, and the patient is kept at bed rest horizontal for 2 nights to discourage CSF fistulization of the wound.
Study: NCT00941174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 13C5-Calcium-L-Leucovorin
Description: This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 13C5-Calcium-L-Leucovorin
Description: This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.
Study: NCT01036360

Intervention type: OTHER
Intervention: metabolic chamber
Description: 20 adolescent boys (10 obese and 10 leans) and 20 men (10 obese and 10 lean) will complete a sub-maximal test on a ergo cycle to draw their linear relationship between VO2 and Fc. Then they will enter a metabolic chamber three times, for 24 hours each
Study: NCT03407781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BBN-IRDye800CW
Description: PET/NIR fluorescent imaging-guided surgery
Study: NCT00452803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)
Study: NCT04057716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: Participants will be asked to extend their time in bed to 11 hours each night for one week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: Participants will be asked to extend their time in bed to 11 hours each night for one week.
Study: NCT03650946

Intervention type: DIAGNOSTIC_TEST
Intervention: Ga-68 PSMA PET
Description: Ga-68 PSMA PET
Study: NCT00452803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiation therapy
Description: Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 \& 8 q 3weeks, Pre-OP \& post-op : 2cycles (total 4 cycles)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiation therapy
Description: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
Study: NCT01425385

Intervention type: OTHER
Intervention: Near infrared spectroscopy monitoring
Description: This is an observational study without interventions

Intervention type: OTHER
Intervention: Autoregulation monitoring
Description: There are no interventions in this observational study
Study: NCT01742429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth subsalicylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: antibiotic
Study: NCT03713190

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin
Description: Sodium-glucose co-transporter 2 (SGLT2), a low-affinity, high-capacity member of an increasingly numerous family of co-transporters, is highly expressed in the proximal renal tubule, and account for the majority of the reabsorption of filtered glucose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A substance without specific pharmacology principles
Study: NCT03258892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive STG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive STG

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies